Compass Therapeutics (CMPX) Stock Forecast & Price Target

Compass Therapeutics Inc's focus on proprietary antibody therapeutics for oncology demonstrates significant clinical potential, especially highlighted by positive colorectal cancer data that showcases higher response rates and improved outcomes in specific tumor types. The company's expanded pipeline, particularly with candidates like CTX-8371 showing a differentiated safety profile and activity across multiple indications, positions it well for further development and potential market introduction. Although R&D expenses have increased, the corresponding decline in G&A expenses indicates efficient management of operational costs, which combined with promising trial results suggests substantial upside for the company’s stock as it explores expanded treatment indications and regulatory pathways.

Compass Therapeutics Inc. has reported a significant increase in net losses, with a Q3 2025 loss of $14.3 million compared to $10.5 million in the same period the previous year, primarily due to heightened research and development expenditures linked to CTX-10726. The company's recent clinical data indicates that the projected adoption of its therapies may be adversely affected by issues such as poor tolerability, indicated by a failed bispecific drug trial and high toxicity risks leading to treatment discontinuation. Furthermore, uncertainty surrounding overall survival outcomes and the variability in clinical data raises concerns regarding the efficacy of Compass Therapeutics's product candidates, diminishing investor confidence in the company's future prospects.